{"denoms":[{"counts":[{"groupId":"BG000","value":"228"},{"groupId":"BG001","value":"225"},{"groupId":"BG002","value":"453"}],"units":"Participants"}],"groups":[{"description":"During each 21-day cycle, participants received pembrolizumab 200 mg intravenously (IV) on Day 1 PLUS etoposide 100 mg/m\\^2 IV on Days 1, 2 and 3 PLUS investigator's choice of platinum therapy (carboplatin titrated to an area under the plasma drug concentration-time curve \\[AUC\\] 5 IV on Day 1 OR cisplatin 75 mg/m\\^2 IV on Day 1). Participants who stopped pembrolizumab as a result of obtaining a response of stable disease (SD), partial response (PR), complete response (CR) or those who stopped after receiving pembrolizumab for 24 months for reasons other than disease progression or intolerability, were eligible for up to an additional 1 year of treatment after progressive disease if they met the criteria for retreatment.","id":"BG000","title":"Pembrolizumab+EP"},{"description":"During each 21-day cycle, participants received placebo (normal saline solution) IV on Day 1 PLUS etoposide 100 mg/m\\^2 IV on Days 1, 2 and 3 PLUS investigator's choice of platinum therapy (carboplatin titrated to an AUC 5 IV on Day 1 OR cisplatin 75 mg/m\\^2 IV on Day 1).","id":"BG001","title":"Placebo+EP"},{"description":"Total of all reporting groups","id":"BG002","title":"Total"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"8.4","value":"64.2"},{"groupId":"BG001","spread":"8.2","value":"65.2"},{"groupId":"BG002","spread":"8.3","value":"64.7"}]}]}],"dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","title":"Age, Continuous","unitOfMeasure":"Years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"76"},{"groupId":"BG001","value":"83"},{"groupId":"BG002","value":"159"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"152"},{"groupId":"BG001","value":"142"},{"groupId":"BG002","value":"294"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"6"},{"groupId":"BG001","value":"13"},{"groupId":"BG002","value":"19"}],"title":"Hispanic or Latino"},{"measurements":[{"groupId":"BG000","value":"204"},{"groupId":"BG001","value":"192"},{"groupId":"BG002","value":"396"}],"title":"Not Hispanic or Latino"},{"measurements":[{"groupId":"BG000","value":"18"},{"groupId":"BG001","value":"20"},{"groupId":"BG002","value":"38"}],"title":"Unknown or Not Reported"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Ethnicity (NIH/OMB)","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}],"title":"American Indian or Alaska Native"},{"measurements":[{"groupId":"BG000","value":"52"},{"groupId":"BG001","value":"34"},{"groupId":"BG002","value":"86"}],"title":"Asian"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}],"title":"Native Hawaiian or Other Pacific Islander"},{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"1"}],"title":"Black or African American"},{"measurements":[{"groupId":"BG000","value":"162"},{"groupId":"BG001","value":"177"},{"groupId":"BG002","value":"339"}],"title":"White"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"1"}],"title":"More than one race"},{"measurements":[{"groupId":"BG000","value":"13"},{"groupId":"BG001","value":"13"},{"groupId":"BG002","value":"26"}],"title":"Unknown or Not Reported"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Race (NIH/OMB)","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"60"},{"groupId":"BG001","value":"56"},{"groupId":"BG002","value":"116"}]}],"title":"ECOG = 0"},{"categories":[{"measurements":[{"groupId":"BG000","value":"168"},{"groupId":"BG001","value":"169"},{"groupId":"BG002","value":"337"}]}],"title":"ECOG = 1"}],"description":"An ECOG Performance Status of 0 (Fully active, able to carry on all pre-disease performance without restriction) or 1 (Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature) was required for inclusion in the study and randomization was stratified by ECOG score.","paramType":"COUNT_OF_PARTICIPANTS","title":"Eastern Cooperative Oncology Group (ECOG) Performance Status","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"100"},{"groupId":"BG001","value":"95"},{"groupId":"BG002","value":"195"}]}],"title":"LDH = ≤ Upper Limit of Normal"},{"categories":[{"measurements":[{"groupId":"BG000","value":"127"},{"groupId":"BG001","value":"129"},{"groupId":"BG002","value":"256"}]}],"title":"LDH = > Upper Limit of Normal"},{"categories":[{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"2"}]}],"title":"LDH Result Missing"}],"description":"Randomization of participants in the study was stratified by LDH measurement at baseline ( ≤ or \\> upper limit of normal).","paramType":"COUNT_OF_PARTICIPANTS","title":"Lactate Dehydrogenase (LDH) Status at Baseline","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"63"},{"groupId":"BG001","value":"66"},{"groupId":"BG002","value":"129"}]}],"title":"Cisplatin"},{"categories":[{"measurements":[{"groupId":"BG000","value":"161"},{"groupId":"BG001","value":"156"},{"groupId":"BG002","value":"317"}]}],"title":"Carboplatin"},{"categories":[{"measurements":[{"groupId":"BG000","value":"4"},{"groupId":"BG001","value":"3"},{"groupId":"BG002","value":"7"}]}],"title":"Not Treated with Platinum Therapy"}],"description":"Randomization of participants was stratified by type of platinum therapy administered during the study.","paramType":"COUNT_OF_PARTICIPANTS","title":"Platinum Therapy Administered","unitOfMeasure":"Participants"}],"populationDescription":"All participants randomized by intention to treat (ITT)."}